Outpatient therapeutic nuclear oncology.
Identifieur interne : 000B57 ( Main/Exploration ); précédent : 000B56; suivant : 000B58Outpatient therapeutic nuclear oncology.
Auteurs : RBID : pubmed:22222779English descriptors
- KwdEn :
- MESH :
- methods : Ambulatory Care, Nuclear Medicine, Radiotherapy.
- radiotherapy : Neoplasms.
- Humans.
Abstract
In the beginning, nuclear medicine was radionuclide therapy, which has evolved into molecular tumour-targeted control of metastatic cancer. Safe, efficacious, clinical practice of therapeutic nuclear oncology may now be based upon accurate personalised dosimetry by quantitative gamma SPECT/CT imaging to prescribe tumoricidal activities without critical organ toxicity. Preferred therapy radionuclides possess gamma emission of modest energy and abundance to enable quantitative SPECT/CT imaging for calculation of the beta therapy dosimetry, without radiation exposure risk to hospital personnel, carers, family or members of the public. The safety of outpatient radiopharmaceutical therapy of cancer with Iodine-131, Samarium-153, Holmium-166, Rhenium-186, Rhenium-188, Lutetium-177 and Indium-111 is reviewed. Measured activity release rates and radiation exposure to carers and the public are all within recommendations and guidelines of international regulatory agencies and, when permitted by local regulatory authorities allow cost-effective, safe, outpatient radionuclide therapy of cancer without isolation in hospital.
DOI: 10.1007/s12149-011-0566-z
PubMed: 22222779
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Outpatient therapeutic nuclear oncology.</title><author><name sortKey="Turner, J Harvey" uniqKey="Turner J">J Harvey Turner</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine, Fremantle Hospital, The University of Western Australia, Alma Street, Fremantle, WA, 6160, Australia. Harvey.Turner@health.wa.gov.au</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Nuclear Medicine, Fremantle Hospital, The University of Western Australia, Alma Street, Fremantle, WA, 6160</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="doi">10.1007/s12149-011-0566-z</idno><idno type="RBID">pubmed:22222779</idno><idno type="pmid">22222779</idno><idno type="wicri:Area/Main/Corpus">000F71</idno><idno type="wicri:Area/Main/Curation">000F71</idno><idno type="wicri:Area/Main/Exploration">000B57</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ambulatory Care (methods)</term><term>Humans</term><term>Neoplasms (radiotherapy)</term><term>Nuclear Medicine (methods)</term><term>Radiotherapy (methods)</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Ambulatory Care</term><term>Nuclear Medicine</term><term>Radiotherapy</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the beginning, nuclear medicine was radionuclide therapy, which has evolved into molecular tumour-targeted control of metastatic cancer. Safe, efficacious, clinical practice of therapeutic nuclear oncology may now be based upon accurate personalised dosimetry by quantitative gamma SPECT/CT imaging to prescribe tumoricidal activities without critical organ toxicity. Preferred therapy radionuclides possess gamma emission of modest energy and abundance to enable quantitative SPECT/CT imaging for calculation of the beta therapy dosimetry, without radiation exposure risk to hospital personnel, carers, family or members of the public. The safety of outpatient radiopharmaceutical therapy of cancer with Iodine-131, Samarium-153, Holmium-166, Rhenium-186, Rhenium-188, Lutetium-177 and Indium-111 is reviewed. Measured activity release rates and radiation exposure to carers and the public are all within recommendations and guidelines of international regulatory agencies and, when permitted by local regulatory authorities allow cost-effective, safe, outpatient radionuclide therapy of cancer without isolation in hospital.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22222779</PMID><DateCreated><Year>2012</Year><Month>05</Month><Day>21</Day></DateCreated><DateCompleted><Year>2012</Year><Month>09</Month><Day>20</Day></DateCompleted><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1864-6433</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>Annals of nuclear medicine</Title><ISOAbbreviation>Ann Nucl Med</ISOAbbreviation></Journal><ArticleTitle>Outpatient therapeutic nuclear oncology.</ArticleTitle><Pagination><MedlinePgn>289-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12149-011-0566-z</ELocationID><Abstract><AbstractText>In the beginning, nuclear medicine was radionuclide therapy, which has evolved into molecular tumour-targeted control of metastatic cancer. Safe, efficacious, clinical practice of therapeutic nuclear oncology may now be based upon accurate personalised dosimetry by quantitative gamma SPECT/CT imaging to prescribe tumoricidal activities without critical organ toxicity. Preferred therapy radionuclides possess gamma emission of modest energy and abundance to enable quantitative SPECT/CT imaging for calculation of the beta therapy dosimetry, without radiation exposure risk to hospital personnel, carers, family or members of the public. The safety of outpatient radiopharmaceutical therapy of cancer with Iodine-131, Samarium-153, Holmium-166, Rhenium-186, Rhenium-188, Lutetium-177 and Indium-111 is reviewed. Measured activity release rates and radiation exposure to carers and the public are all within recommendations and guidelines of international regulatory agencies and, when permitted by local regulatory authorities allow cost-effective, safe, outpatient radionuclide therapy of cancer without isolation in hospital.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>J Harvey</ForeName><Initials>JH</Initials><Affiliation>Department of Nuclear Medicine, Fremantle Hospital, The University of Western Australia, Alma Street, Fremantle, WA, 6160, Australia. Harvey.Turner@health.wa.gov.au</Affiliation></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Ann Nucl Med</MedlineTA><NlmUniqueID>8913398</NlmUniqueID><ISSNLinking>0914-7187</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Ambulatory Care</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Nuclear Medicine</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiotherapy</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2012</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1007/s12149-011-0566-z</ArticleId><ArticleId IdType="pubmed">22222779</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B57 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B57 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22222779
|texte= Outpatient therapeutic nuclear oncology.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22222779" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |